Top

Published in:

01-07-2013 | Epidemiology

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study

Authors: Natalia Garcia-Giralt, María Rodríguez-Sanz, Daniel Prieto-Alhambra, Sonia Servitja, Elisa Torres-del Pliego, Susana Balcells, Joan Albanell, Daniel Grinberg, Adolfo Diez-Perez, Ignasi Tusquets, Xavier Nogués

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

A major side effect of aromatase inhibitor (AI) therapy is AI-related arthralgia (AIA), which often leads to therapy discontinuation. We aimed to identify genetic variants associated with AIA and therapy discontinuation in the first year of AI treatment. Our prospective cohort study included 343 postmenopausal women with early breast cancer starting AI therapy. Single nucleotide polymorphisms (SNPs) in candidate genes involved in estrogen and vitamin D signaling were selected. Univariate and multivariate linear/logistic regressions were fitted in order to asses the association between studied SNPs and AIA intensity (visual analogic scale score) at 3 and 12 months of follow-up, worsening pain, and therapy discontinuation. We also tested for a priori-defined interactions by introducing multiplicative terms in the regression equations. SNPs in CYP17A1 and VDR genes appeared significantly associated with AIA (P = 0.003, P = 0.012, respectively). One SNP in CYP27B1 gene was related to therapy discontinuation [P = 0.02; OR 0.29 (0.09–0.99)]. We revealed interactions between CYP27B1 and both CYP17A1 (P = 0.01) and VDR SNPs (P = 0.06). Furthermore, an additive effect on pain intensity was shown for unfavorable alleles, with two points higher mean absolute pain increase and up to 5.3-fold higher risk of worsening pain compared to favorable genotypes. SNPs in CYP17A1, VDR, and CYP27B1 genes predict the risk of AIA. Their determination would be useful to trigger the monitoring strategies in women at risk of therapy discontinuation.

Kudachadkar R, O’Regan RM (2005) Aromatase Inhibitors as adjuvant therapy for postmenopausal patients with early stage breast Cancer. CA Cancer J Clin 55:145–163. doi:10.3322/canjclin.55.3.145 PubMedCrossRef

Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98:1802–1810. doi:10.1002/cncr.11745 PubMedCrossRef

Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936–942. doi:10.1200/jco.2011.38.0261 PubMedCrossRef

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883. doi:10.1200/jco.2007.10.7573 PubMedCrossRef

Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman J-AW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang L, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM (2010) Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674–4682. doi:10.1200/jco.2010.28.5064 PubMedCrossRef

Mao J, Su HI, Feng R, Donelson M, Aplenc R, Rebbeck T, Stanczyk F, DeMichele A (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8. doi:10.1186/bcr2813 PubMedCrossRef

Flores CA, Shughrue P, Petersen SL, Mokha SS (2003) Sex-related differences in the distribution of opioid receptor-like 1 receptor mRNA and colocalization with estrogen receptor mRNA in neurons of the spinal trigeminal nucleus caudalis in the rat. Neuroscience 118:769–778PubMedCrossRef

Blomqvist A (2000) Sex hormones and pain: a new role for brain aromatase? J Comp Neurol 423:549–551. doi:10.1002/1096-9861(20000807 PubMedCrossRef

Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthr Rheum 52:2594–2598CrossRef

10.

Cvoro A, Tatomer D, Tee M-K, Zogovic T, Harris HA, Leitman DC (2008) Selective estrogen receptor-Î² agonists repress transcription of proinflammatory genes. J Immunol 180:630–636PubMed

11.

Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26:3147–3152. doi:10.1200/JCO.2007.15.4005 PubMedCrossRef

12.

Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I (2010) Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas 66:291–297. doi:10.1016/j.maturitas.2010.03.012 PubMedCrossRef

13.

Prieto-Alhambra D, Javaid M, Servitja S, Arden N, Martinez-GarcÃa M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2010) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125:869–878. doi:10.1007/s10549-010-1075-9 PubMedCrossRef

14.

Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I (2011) Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. The Breast 21(1):95–101. doi:10.1016/j.breast.2011.09.001 PubMedCrossRef

15.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629. doi:10.1200/jco.2005.09.121 PubMedCrossRef

16.

Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O’Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung C-L, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen A-L, Zhai G, Macdonald HM, Forouhi NG, Loos RJF, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson J-O, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin M-R, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 376:180–188. doi:10.1016/S0140-6736(10)60588-0 CrossRef

17.

Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H (1996) Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res 11:306–311PubMedCrossRef

18.

Enjuanes A, Garcia-Giralt N, Supervía A, Nogués X, Ruiz-Gaspà S, Bustamante M, Mellibovsky L, Grinberg D, Balcells S, Díez-Pérez A (2006) A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone 38:738–743PubMedCrossRef

19.

Zarrabeitia MT, Hernandez JL, Valero C, Zarrabeitia AL, Garcia-Unzueta M, Amado JA, Gonzalez-Macias J, Riancho JA (2004) A common polymorphism in the 5′-untranslated region of the aromatase gene influences bone mass and fracture risk. Eur J Endocrinol 150:699–704. doi:10.1530/eje.0.1500699 PubMedCrossRef

20.

Langdahl G, Brixen E (2000) Polymorphisms in the vitamin D receptor gene and bone mass, bone turnover and osteoporotic fractures. Eur J Clin Invest 30:608–617PubMedCrossRef

21.

Todd KH, Funk JP (1996) The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 3:142–146. doi:10.1111/j.1553-2712.1996.tb03402.x PubMedCrossRef

22.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 57:289–300. doi:10.2307/2346101

23.

Dhir V, Ivison HE, Krone N, Shackleton CHL, Doherty AJ, Stewart PM, Arlt W (2007) Differential inhibition of CYP17A1 and CYP21A2 activities by the P450 oxidoreductase mutant A287P. Mol Endocrinol 21:1958–1968. doi:10.1210/me.2007-0066 PubMedCrossRef

24.

Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM (2009) Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy. Cancer Nurs 32:143–150. doi:10.1097/01.NCC.0000339262.44560.92 PubMedCrossRef

25.

Arai H, Miyamoto K-I, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y, Takeda E (2001) The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 16:1256–1264. doi:10.1359/jbmr.2001.16.7.1256 PubMedCrossRef

26.

Takeyama K-I, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S (1997) 25-Hydroxyvitamin D3 1α-hydroxylase and vitamin D synthesis. Science 277:1827–1830. doi:10.1126/science.277.5333.1827 PubMedCrossRef

27.

Rastelli A, Taylor M, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis M (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129:107–116. doi:10.1007/s10549-011-1644-6 PubMedCrossRef

28.

Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group. Cancer Treat Rev 34(suppl 1):S3–S18. doi:10.1016/j.ctrv.2008.03.007 PubMedCrossRef

29.

Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19:1407–1416. doi:10.1093/annonc/mdn164 PubMedCrossRef

30.

Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L (2008) Plasma 1,25(OH)2D levels decrease in postmenopausal women with hypovitaminosis D. Eur J Endocrinol 158:571–576. doi:10.1530/EJE-07-0844 PubMed

Title: Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study
Authors: Natalia Garcia-Giralt
María Rodríguez-Sanz
Daniel Prieto-Alhambra
Sonia Servitja
Elisa Torres-del Pliego
Susana Balcells
Joan Albanell
Daniel Grinberg
Adolfo Diez-Perez
Ignasi Tusquets
Xavier Nogués
Publication date: 01-07-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2638-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer

Early predictors of not returning to work in low-income breast cancer survivors: a 5-year longitudinal study

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy

Tumour diploidy and survival in breast cancer patients with BRCA2 mutations

Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time

Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast

Keynote webinar | Spotlight on antibody–drug conjugates in cancer